Category: Parkinson’s Disease: Clinical Trials
Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy can slow disease progression by modulating circadian rhythms and mitochondrial function in neurons.
Background: Emerging research suggests that exposure to specific light wavelengths can have profound effects on neurodegeneration, potentially offering neuroprotective benefits. In Parkinson’s Disease (PD), where dopaminergic neurons in the brain progressively degenerate, there’s a critical need for innovative interventions that slow this process.
Method: In this longitudinal study, 100 early-stage PD patients (Hoehn and Yahr Stage 1-2) were enrolled and divided into two groups: one receiving diurnal light exposure and a placebo group. The intervention was delivered through specially designed glasses for two hours daily over 12 months. Neurodegeneration rates were assessed using serial positron emission tomography (PET) scans targeting dopaminergic neuron integrity, alongside neuropsychological evaluations and circadian rhythm assessments using actigraphy. Statistical techniques were used to analyze changes over time and between groups.
Results: Upon completion, the intervention group showed a statistically significant reduction in the rate of dopaminergic neuron degeneration, with a 30% lesser decline in PET scan biomarker degradation than the control group (95% CI: 25% – 35%, p<0.001). This group also showed improved circadian rhythm markers, with more regulated sleep/wake cycles (p<0.01) and increased daytime activity (p<0.05). Neuropsychological tests indicated significant improvements in cognitive domains linked to executive and visuospatial skills in the intervention group, without similar improvements observed in the placebo group (p<0.05).
Conclusion: Customized diurnal light exposure is a non-invasive, effective strategy for neuroprotection in early-stage Parkinson’s disease, slowing neuron degeneration via circadian rhythm and mitochondrial functions. This promising approach paves the way for further research into light therapies for PD and similar conditions, with potential for symptom management and disease progression impact.
To cite this abstract in AMA style:
S. Putri, R. Fajar, E. Syafruddin. Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/exploring-the-neuroprotective-effects-of-diurnal-light-exposure-in-early-stage-parkinsons-disease-a-longitudinal-multi-sensory-intervention-study/. Accessed October 5, 2024.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/exploring-the-neuroprotective-effects-of-diurnal-light-exposure-in-early-stage-parkinsons-disease-a-longitudinal-multi-sensory-intervention-study/